Jaguar Health shareholders OK reverse stock split; crofelemer POC data and FDA meeting expected Q2 2025

Jaguar Health, Inc.

Shareholders voted 5,281,329 for and 1,377,494 against the reverse stock split (ratio 1:15 to 1:40); board to set exact ratio by March 2026.
First proof-of-concept investigator-initiated trial results for crofelemer in SBS-IF and MVID are expected in Q2 2025.
Company expects FDA meeting in Q2 2025 to discuss Phase 3 OnTarget breast cancer subgroup results and potential approval path.
Adjournment proposal also approved with 5,423,671 for and 1,163,222 against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.